Fig. 3.
Fig. 3. Botrocetin-induced binding of rvWF-WT and type 2M rvWFs to platelets. / rvWF-WT (□) or mutated rvWF (I662F (♦), G561A (x), E596K (•), and R611H (●; 0.4 μg/mL) labeled with 125I-MoAb 505 were incubated with paraformaldehyde-fixed platelets (108/mL) for 1 hour at room temperature in the presence of varying concentrations of botrocetin (0-1 μg/mL). Results were expressed as the specific binding of 125I-MoAb 505/rvWF complexes to platelets as described in the “Materials and methods” section. Binding estimated using mock-transfected cell medium was < 5%. Results are from a typical experiment performed in duplicate.

Botrocetin-induced binding of rvWF-WT and type 2M rvWFs to platelets.

rvWF-WT (□) or mutated rvWF (I662F (♦), G561A (x), E596K (•), and R611H (●; 0.4 μg/mL) labeled with 125I-MoAb 505 were incubated with paraformaldehyde-fixed platelets (108/mL) for 1 hour at room temperature in the presence of varying concentrations of botrocetin (0-1 μg/mL). Results were expressed as the specific binding of 125I-MoAb 505/rvWF complexes to platelets as described in the “Materials and methods” section. Binding estimated using mock-transfected cell medium was < 5%. Results are from a typical experiment performed in duplicate.

Close Modal

or Create an Account

Close Modal
Close Modal